Experimental therapy of rheumatoid arthritis using antibodies against tumor-necrosis-factor;Experimentelle therapie der rheumatoiden arthritis mit antikorpern gegen tumor-nekrose-faktor

Zeitschrift fur Rheumatologie

Volumn 57, Issue 5, 1998, Pages 298-301

  Manger, B ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN ANTIBODY COMPLEX; CONFERENCE PAPER; EXPERIMENTAL TEST; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031739803     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930050115     Document Type: Conference Paper

References (15)

1. Alsalameh S, Kalden JR, Burmester GR (1991) Die Rolle von Zytokinen und Wachstumsfaktoren bei der rheumatoiden Gelenkdestruktion. Z Rheumatol 50:347-359
2. Brennan FM, Browne Ka, Green PA, Jaspar JM, Maini RN, Feldmann M (1997) Reduction of serum matrix metalloproteinase 1 and serum matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α therapy. Br J Rheumatol 36: 643-650
3. Burmester GR, Manger B, Kalden J (1995) Immunpathogenese entzündlichrheumatischer Erkrankungen. Dt Ärztebl 92:A1010-1020
4. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumour necrosis factor α in synovial tissues and at the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125-1132
5. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α. Arthritis Rheum 36:1681-1690
6. Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus palcebo in rheumatoid ar-thritis. Lancet 344:1105-1110
7. Ibelgaufts H (1992) Lexikon Zytokine. Medikon Verlag München
8. Kalden JR, Manger B (1995) New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis. Br J Rheumatol 34:193-199
9. Kalden JR, Manger B (1996) Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 8:195-200
10. Kalden-Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kalden JR (1997) NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatology Int 16:249-255
11. Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N. Nüsslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNF-alpha by i. v. infusion of a chimeric, monoclonal TNF-alpha antibody inpatients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 156:1646-1653
12. Maini RN (1997) Monoclonal anti. TNFα antibody (cA2) in the treatment of rheumatoid arthritis. In: Proceedings of the XIXthe ILAR Congress of Rheumatology (Ed: Feng PH) 459-464. Communications Consultants, Singapore
13. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334-342
14. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077-1081
15. Winter G, Harris WJ (1993) Humanized antibodies. Immunol Today 14:243-246